Cyril Konto | Source | Oncologist, President and CEO at Ichnos Sciences

Cyril Konto, M.D. has served as Chief Medical Officer since joining Ichnos and as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies. At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. He began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.